Clinical Trial Update: S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial of bortezomib, thalidomide, and dexamethasone in relapsed or refractory multiple myeloma; study terminated with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Thalidomide (thalidomide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2013-04-19